I applaude the announcement in a chain of events that confirms...

I applaude the announcement in a chain of events that confirms ADR is a great tech company. To survive it needs to be a geat business to.

In Sept 2021 ADR announced clearance of their 1st next gen physiological sensor
March 2022 FIrst batch of the above completed ready for sale
Clearance for Ellipta July 2022;
Filing for GSK MDIs; August 2022
Filing for Teva MDIs August 2022
Clearance for GSK November 2022
Jan 2023 6 montsh later first batch made

If they continue to deliver the March 2021 product development map, by Feb 2023 they will have to support all their current sensors, the AZ relationship, current clinical trials, a complete portfolio of 4 new next gen sensors and the software to manage and maintain it while in the UK committing their limited resources to what in real terms is a small ($800k) 12 month research contract . With their limited people resources are they stretching themselves too thin ? Will the announced UK contract be a distraction vs focusing on the US which they agree is their primary focus ? This is a great problem to have and is a classic example of where success can lead to failure.

The continued elephant in the room is sales. They have a great range of high tech and expensive product in the showroom with full reimbursement in the US for the "next gen" since RPM since 2019 and full reimbursement for "old gen" through RTM since Jan 2021.

Big questions, why no orders or sales in the US ? What is stopping customers buying ? Someone from ADR needs to be on the ground understanding the roadblocks and remove them. Can ADR do what they have never done and commercialise this business ? There seem's to be no barrier now, but still, something is missing somewhere? Its just not obvious what it is. Guys, please find the answer.